Findings

What do systematic reviews say?

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings ‐ PEP vs PDPV

Exercise capacity · adults and children with CF

1 finding from 1 review

Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Low

Summary of findings ‐ PEP vs PDPV

Well being: QWB scale · adults and children with CF

1 finding from 1 review

Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Low

Summary of findings ‐ PEP vs PDPV

LCI · adults and children with CF

The review found no eligible studies for this question.

1 finding from 1 review

Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ PEP vs PDPV

Adverse events · adults and children with CF

1 finding from 1 review

Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 66 participants
Low

Summary of findings ‐ PEP vs oscillating PEP

FEV1 % predicted: absolute change from baseline · adults and children with CF

1 finding from 1 review

Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 217 participants
Moderate

Summary of findings ‐ PEP vs oscillating PEP

Number of respiratory exacerbations: requiring either IV antibiotics or hospitalisation · adults and children with CF

1 finding from 1 review

Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 112 participants
Moderate

Early vs deferred AST

Time to death from any cause (here: overall mortality at 12‐month · advanced hormone‐sensitive prostate cancer

Early probably leads to lower time to death of any cause (here: all‐cause mortality at 5 years) compared with deferred AST (moderate certainty).

1 finding from 1 review

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
HR 0.82 [0.75, 0.9]
10 studies · 4767 participants
Moderate

Early vs deferred AST

Serious adverse events · advanced hormone‐sensitive prostate cancer

Early showed no clear difference in serious adverse events compared with deferred AST (low certainty).

1 finding from 1 review

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
RR 1.05 [0.95, 1.16]
5 studies · 10575 participants
Low

Early vs deferred AST

Time to death from prostate cancerMedian · advanced hormone‐sensitive prostate cancer

Early probably leads to lower time to death from prostate cancer (here: prostate cancer mortality… compared with deferred AST (moderate certainty).

1 finding from 1 review

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
HR 0.69 [0.57, 0.84]
7 studies · 3677 participants
Moderate

Early vs deferred AST

Skeletal events · advanced hormone‐sensitive prostate cancer

Early may leads to lower skeletal events compared with deferred AST (low certainty).

1 finding from 1 review

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
RR 0.37 [0.17, 0.8]
3 studies · 2209 participants
Low

Early vs deferred AST

Fatigue · advanced hormone‐sensitive prostate cancer

Early may leads to higher fatigue compared with deferred AST (low certainty).

1 finding from 1 review

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
RR 1.41 [1.23, 1.62]
2 studies · 8209 participants
Low

Early vs deferred AST

Heart failure · advanced hormone‐sensitive prostate cancer

Early may leads to higher heart failure compared with deferred AST (low certainty).

1 finding from 1 review

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
RR 1.9 [1.09, 3.33]
1 study · 1214 participants
Low

Early vs deferred AST

Global quality of life · advanced hormone‐sensitive prostate cancer

1 finding from 1 review

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 285 participants
Moderate

Clobazam vs placebo

50% or greater reduction in seizure frequency Number of seizures · patients with drug‐resistant epilepsy

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 47 participants
Very low

Clobazam vs placebo

Seizure freedom · patients with drug‐resistant epilepsy

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 175 participants
Very low

Clobazam vs placebo

Treatment withdrawal · patients with drug‐resistant epilepsy

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 197 participants
Very low

Clobazam vs placebo

Withdrawals due to adverse events · patients with drug‐resistant epilepsy

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 150 participants
Very low

Clobazam vs placebo

50% reduction in generalised‐onset seizure frequency Not measured · patients with drug‐resistant epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobazam vs placebo

50% reduction in focal‐onset seizure frequency Not measured · patients with drug‐resistant epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Severity of post‐thrombotic syndromeb ( · adults with PTS

1 finding from 1 review

Compression therapy for treating post‐thrombotic syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 69 participants
Very low